Vistagen Therapeutics, Inc. 8-K Filing
Ticker: VTGN · Form: 8-K · Filed: Dec 22, 2025 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | Dec 22, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Vistagen Therapeutics, Inc. (ticker: VTGN) to the SEC on Dec 22, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ich registered Common Stock, par value $0.001 per share VTGN Nasdaq Capital Market).
How long is this filing?
Vistagen Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 458 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 458 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-12-22 17:29:13
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VTGN Nasdaq Capital Market
Filing Documents
- vtgn-20251217.htm (8-K) — 21KB
- 0001628280-25-058594.txt ( ) — 132KB
- vtgn-20251217.xsd (EX-101.SCH) — 2KB
- vtgn-20251217_lab.xml (EX-101.LAB) — 21KB
- vtgn-20251217_pre.xml (EX-101.PRE) — 12KB
- vtgn-20251217_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On December 17, 2025, Vistagen Therapeutics, Inc. (the " Company ") announced that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not achieve its primary endpoint, as measured by the least squares (" LS" ) mean change from baseline on the the Subjective Units of Distress Scale score for fasedienol (13.6 +/-1.54 standard error, SE) compared with placebo (14.0 +/-1.51 SE). There was no treatment difference between fasedienol and placebo for the secondary endpoints. The favorable safety data of fasedienol were consistent with previously completed clinical trials.
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc. Date: December 22, 2025 By: /s/ Shawn K. Singh Shawn K. Singh President and Chief Executive Officer